Non-invasive MRD Assessment in Multiple Myeloma

Inclusion Criteria: * Adults age ≥18 years * Patients with newly diagnosed multiple myeloma * Patients with previously treated multiple myeloma with a maximum of two prior lines of therapy * Expected life expectancy of greater than one year and intention to start a new line of treatment Exclusion Criteria: * Patients without cognitive capacity to give informed consent for participation * Patients with contraindications to MRI, which include the following: * Claustrophobia, which, at investigator's discretion, would prohibit patient from undergoing whole body diffusion-weighted magnetic resonance imaging (WB-DWI) * Pacemaker * Metallic implants, which would prohibit patient from undergoing MRI All subjects will be screened for any contraindication to MRI as per their guidelines at the time of patient enrollment. * Patients must not receive granulocyte colony stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF) injection within 1 week prior to WB-DWI. * Patients must not have been initiated on treatment prior to baseline disease assessment by bone marrow aspiration/biopsy and/or WB-DWI Up to 160 mg of dexamethasone (or equivalent) and/or 1 dose of bortezomib (+/- Cyclophosphamide-Dexamethasone) is allowed prior to disease assessment by bone marrow aspiration and WB-DWI.